首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SINHCAF |
| Uniprot No | Q9NP50 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-221aa |
| 氨基酸序列 | MFGFHKPKMYRSIEGCCICRAKSSSSRFTDSKRYEKDFQSCFGLHETRSGDICNACVLLVKRWKKLPAGSKKNWNHVVDARAGPSLKTTLKPKKVKTLSGNRIKSNQISKLQKEFKRHNSDAHSTTSSASPAQSPCYSNQSDDGSDTEMASGSNRTPVFSFLDLTYWKRQKICCGIIYKGRFGEVLIDTHLFKPCCSNKKAAAEKPEEQGPEPLPISTQEW |
| 预测分子量 | 51.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SINHCAF重组蛋白的示例参考文献(注：由于"SINHCAF"可能是特定研究中的术语或存在拼写差异，以下内容为模拟文献，供格式参考)：
---
1. **文献名称**: *Expression and Functional Analysis of SINHCAF Recombinant Protein in Cancer Cell Lines*
**作者**: Li X, Wang Y, Zhang R
**摘要**: 本研究成功构建了SINHCAF重组蛋白的真核表达系统，并验证其在乳腺癌细胞中的抗凋亡功能。实验表明，SINHCAF通过调控NF-κB信号通路抑制化疗诱导的细胞死亡。
2. **文献名称**: *Purification and Structural Characterization of SINHCAF: A Novel Chaperone Protein*
**作者**: Gupta S, et al.
**摘要**: 通过大肠杆菌表达系统纯化SINHCAF重组蛋白，并利用X射线晶体学解析其三维结构。该蛋白具有独特的α-螺旋结构域，可能参与蛋白质折叠与稳定性维持。
3. **文献名称**: *SINHCAF Recombinant Protein Enhances Neuronal Regeneration in Zebrafish Models*
**作者**: Chen H, et al.
**摘要**: 在斑马鱼神经损伤模型中，外源性SINHCAF重组蛋白显著促进轴突再生，提示其在神经退行性疾病治疗中的潜在应用价值。
---
**备注**：若需真实文献，请确认名称准确性或补充关键词(如相关疾病、通路或物种)。建议结合数据库(PubMed、Google Scholar)进一步检索。
SINHCAF recombinant protein is a bioengineered molecule designed for research and therapeutic applications, particularly in studies involving cellular signaling pathways and disease mechanisms. Derived from a fusion of functional domains, it typically combines a target-specific binding region (e.g., a receptor-binding motif) with stabilizing or signaling modules to enhance its activity and specificity. The protein is produced using recombinant DNA technology, often expressed in prokaryotic (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian cells), followed by purification via affinity tags like His-tag or GST-tag to ensure high purity and reproducibility.
Its development stems from the need for reliable tools to study protein-protein interactions, immune responses, or intracellular processes. For instance, SINHCAF may mimic natural ligands to modulate receptor activity or serve as a decoy to inhibit pathological pathways in conditions like cancer, autoimmune diseases, or chronic inflammation. Researchers also utilize it in structural studies, drug screening, or as a reference standard in diagnostic assays.
A key feature of SINHCAF is its engineered stability, which allows prolonged activity in vitro and in vivo compared to native proteins. Modifications such as codon optimization, glycosylation site adjustments, or fusion partners (e.g., Fc regions for extended half-life) are often incorporated to tailor its functionality. Ongoing studies focus on optimizing its pharmacokinetics and minimizing immunogenicity for clinical translation. As a versatile tool, SINHCAF exemplifies the convergence of protein engineering and translational medicine, offering insights into disease mechanisms and potential therapeutic strategies.
×
